Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
Summary
- Eligibility
- for people ages 1-17 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Philip Rosenthal
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- ID
- NCT03182907
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Last Updated